Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2015 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress

– Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers – – Provides Update to Certain Trials based on Expanding Clinical Experience...
August 03, 2015 08:00 ET | Source: Karyopharm Therapeutics

Karyopharm to Report Second Quarter 2015 Financial Results on August 10, 2015

NEWTON, Mass., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2015 financial...
June 22, 2015 07:00 ET | Source: Karyopharm Therapeutics

Karyopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at International Conference on Malignant Lymphoma

NEWTON, Mass., June 22, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical and...
June 15, 2015 07:00 ET | Source: Karyopharm Therapeutics

Karyopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting

NEWTON, Mass., June 15, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its...
June 01, 2015 14:15 ET | Source: Karyopharm Therapeutics

Karyopharm Presents Clinical Data for Selinexor (KPT-330) in Patients With Recurrent Glioblastoma and Advanced Sarcomas at 2015 ASCO Annual Meeting

NEWTON, Mass., June 1, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its...
May 30, 2015 14:15 ET | Source: Karyopharm Therapeutics

Karyopharm Presents Clinical Data for Selinexor (KPT-330) in Patients With Heavily Pretreated Gynecological Cancers and Asian Patients With Advanced Malignancies at 2015 ASCO Annual Meeting

NEWTON, Mass., May 30, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its...
May 28, 2015 08:00 ET | Source: Karyopharm Therapeutics

Karyopharm Initiates STORM Clinical Trial of Oral Selinexor (KPT-330) in Multiple Myeloma

NEWTON, Mass., May 28, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the initiation of the STORM study (Selinexor...
May 27, 2015 16:10 ET | Source: Karyopharm Therapeutics

Karyopharm to Present Clinical Data Update for Selinexor (KPT-330) in Solid Tumors

- Presentation to Include Discussion of Selinexor as Single-Agent in Solid Tumor Malignancies Including Gynecologic Cancers, Recurrent Glioblastoma and Advanced Sarcomas - - Webcast Event...
May 21, 2015 07:25 ET | Source: Karyopharm Therapeutics

Karyopharm to Present Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting

- Presentations Include Clinical Data on Activity of Selinexor (KPT-330) in Diffuse Large B-cell Lymphoma and Acute Myeloid Leukemia - - An Oral Presentation to Highlight the Durability of...
May 13, 2015 17:00 ET | Source: Karyopharm Therapeutics

Karyopharm to Present Solid Tumor Data on Lead Drug Candidate Selinexor at 2015 American Society of Clinical Oncology Annual Meeting

NEWTON, Mass., May 13, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that four abstracts describing the activity of...